Swiftly capturing growth opportunities, including M&A
First written in FY2017. 20 of 28 entries say "Advanced", first in FY2018. Latest entry: 2026-10-15.
1 other company's latest entry also says "Cited as achieved".
- 2026-10-15Cited as achievedMonthly
「また、M&Aにより 248 店舗を取得した結果、9月末のスギ薬局グループの総拠点数は2,617拠点となりました。」
M&Aによる店舗取得の実績が月次速報で確認され、成長機会の捕捉が実績として引用されている。 - FY2027-H1AchievedAnnual report
「Based on a resolution of the Board of Directors meeting held on 9 April 2026, the Company additionally acquired shares in its equity-method affiliate 株式会社セキ薬品 on 1 September 2026. As a result, the Company's voting rights ratio became 51.0%, and the company became a consolidated subsidiary of the Company.」
Regarding セキ薬品, the additional acquisition initially targeted for around June 2030 was brought forward, and the company became a consolidated subsidiary on 1 September 2026 with a 51.0% voting rights ratio. - FY2026AdvancedAnnual report
「At a Board of Directors meeting held on 9 April 2026, the Company resolved to make 株式会社セキ薬品, an equity-method affiliate, a consolidated subsidiary by additionally acquiring its shares, and on the same date entered into a memorandum of understanding relating to the "Shareholders' Agreement." The acquisition is scheduled to become effective on 1 September 2026, when 株式会社セキ薬品 is expected to become a consolidated subsidiary of the Company.」
Regarding セキ薬品, it describes the additional acquisition increasing the ownership interest from 49.0% to 51.0% and the planned conversion into a subsidiary on 1 September 2026. - FY2026-H1AdvancedAnnual report
「The acquisition of the shares became effective on 30 September 2025, and 株式会社セキ薬品 became an equity-method affiliate of the Company.」
The acquisition of shares in セキ薬品 became effective on 30 September 2025, making it an equity-method affiliate with a 49.0% ownership interest after the acquisition and an acquisition price of ¥22.5 billion. It also describes an agreement to make an additional acquisition in approximately 5 years, increasing the ownership interest to 51.0%. - FY2026-H1AdvancedAnnual report
「On 19 August 2025, the Company entered into a share transfer agreement to acquire shares in 株式会社セキ薬品.」
Regarding セキ薬品, a share transfer agreement was entered into on 19 August 2025, and the transaction to make it an equity-method affiliate is progressing. - FY2026-H1AdvancedAnnual report
「During the interim period, I&H株式会社, formerly a consolidated subsidiary, was excluded from the scope of consolidation because it was absorbed in a merger in which the Company's consolidated subsidiary 株式会社スギ薬局 was the surviving company.」
Regarding I&H株式会社, an absorption-type merger was completed with スギ薬局 as the surviving company, advancing the integration process. - FY2025AdvancedAnnual report
「The additional shares acquired represented a 33.28% voting rights ratio, and through the transaction I&H株式会社 became a wholly owned subsidiary of the Company.」
Following the acquisition of 66.72% in September 2024, an additional 33.28% was acquired, making I&H株式会社 a wholly owned subsidiary. The objectives are to further strengthen collaboration between the two companies, generate synergies at an early stage, and improve productivity. - FY2025-H1Sale of investee shares and exclusion from the equity methodAnnual report
「During the interim period, the Company's consolidated subsidiary ㈱スギ薬局 sold all shares in ㈱Ｍｅｄｉｐｌａｔ, and the Company sold part of its shares in Greattree Sugi Pharmacy Hong Kong Limited, reducing its ownership interest in the company. As a result, the companies have been excluded from the scope of application of the equity method.」
All shares in investee Mediplat and part of the shares in Greattree Sugi Pharmacy Hong Kong were sold, and the companies were excluded from the scope of application of the equity method. - FY2025-H1AdvancedAnnual report
「At a Board of Directors meeting held on 27 February 2024, the Company resolved to acquire the common shares of I&H株式会社 and make it a subsidiary (the "Transaction"). The Transaction was completed on 2 September 2024 pursuant to the share transfer agreement executed on that date and the amendment agreement relating to the share transfer agreement executed on 30 August 2024.」
Regarding I&H株式会社, which operates dispensing pharmacies, shares were acquired on 2 September 2024 and the company was made a subsidiary with a 66.72% voting rights ratio. - FY2025-Q1Sale of investee sharesAnnual report
「As the Company's consolidated subsidiary ㈱スギ薬局 sold all shares in ㈱Ｍｅｄｉｐｌａｔ during the first quarter of the fiscal year, the company has been excluded from the scope of application of the equity method.」
Regarding Mediplat, which had been acquired in connection with the capture of growth opportunities, all shares were sold and the company was excluded from the scope of application of the equity method. - FY2024-Q2AdvancedAnnual report
「At a Board of Directors meeting held on 16 June 2023, the Company resolved to acquire shares in Japan Hospice Holdings Inc. and entered into a capital and business alliance agreement with the company. The shares were acquired on 3 July 2023. As a result, the company became an equity-method affiliate of the Company.」
The capital and business alliance with Japan Hospice Holdings Inc. and the share acquisition were completed, and the company became an equity-method affiliate. - FY2024-Q1AdvancedAnnual report
「At a Board of Directors meeting held on 16 June 2023, the Company resolved to acquire shares in Japan Hospice Holdings Inc. and entered into a capital and business alliance agreement with the company. The shares were acquired on 3 July 2023. As a result, the company is expected to become an equity-method affiliate of the Company.」
The Company is pursuing growth opportunities in the healthcare and home-care sectors through its capital and business alliance with Japan Hospice Holdings Inc. and the acquisition of shares. - FY2024-Q1AdvancedAnnual report
「During the first quarter of the fiscal year, the Company's consolidated subsidiary スギメディカル株式会社 acquired all shares in 株式会社ＣｏＭｅｄｉＣｓ and made it a subsidiary, so it has been included in the scope of consolidation.」
Regarding the capture of growth opportunities, all shares in 株式会社ＣｏＭｅｄｉＣｓ were acquired and the company was made a subsidiary. - FY2023-Q2AdvancedAnnual report
「During the second quarter of the fiscal year, the Company's consolidated subsidiary S Trading Co., Ltd. acquired all shares in 渡辺貿易株式会社 and made it a subsidiary, so it has been included in the scope of consolidation.」
Regarding the capture of growth opportunities, including M&A, it reports the acquisition of all shares in 渡辺貿易株式会社 and its conversion into a subsidiary as a new achievement. - FY2022-Q3Sale of shares in an equity-method investeeAnnual report
「As all shares in ㈱Ｍ－ａｉｄ, formerly an equity-method affiliate, were sold during the third quarter of the fiscal year, the company has been excluded from the scope of application of the equity method.」
Regarding M-aid, which had been acquired in connection with the capture of growth opportunities, all shares were sold and the company was excluded from the scope of application of the equity method. - FY2021AdvancedAnnual report
「As new services, we will work to enhance corporate value by increasing customer lifetime value in the healthcare sector and expanding revenue through collaboration with other companies as we expand into overseas markets.」
The capture of growth opportunities has been extended to new services in the healthcare sector, overseas market expansion, and revenue growth through collaboration with other companies. It also describes the capital and business alliance with Inagora Holdings in January 2020 and the business alliance with Taiwan's Great Tree Pharmacy in November 2020. - FY2020AdvancedAnnual report
「As the Company acquired shares in ㈱ＨＭＡ during the fiscal year, the company has been included in the scope of consolidation.」
Regarding the capture of growth opportunities, it reports the acquisition of HMA and its conversion into a consolidated subsidiary as a new acquisition achievement. - FY2020-Q3AdvancedAnnual report
「Acquired one home-visit nursing station.」
Regarding the capture of growth opportunities, it reports the concrete achievement of acquiring one home-visit nursing station. - FY2019-Q1AdvancedAnnual report
「During the first quarter of the fiscal year, the Company acquired shares in 株式会社Ｍｅｄｉｐｌａｔ and 株式会社Ｍ－ａｉｄ, making them equity-method affiliates.」
Regarding the capture of growth opportunities, it describes concrete progress through the acquisition of shares in Mediplat and M-aid and their conversion into equity-method affiliates. - FY2018AdvancedAnnual report
「The company decided to subscribe to the third-party allotment capital increases of メドピア株式会社 and 株式会社Ｍｅｄｉｐｌａｔ with the aim of creating an integrated platform combining online and offline services in the health, medical care and nursing care fields and developing and providing distinctive preventive healthcare services centred on “IT × community-based services” through collaboration that leverages the management resources of both groups.」
The capture of growth opportunities, including M&A, has progressed into concrete collaboration with other companies through subscriptions to the third-party allotment capital increases of メドピア, Ｍｅｄｉｐｌａｔ and Ｍ－ａｉｄ. - FY2017First statedAnnual report
「Rapidly capture all growth opportunities, including M&A, while actively expanding stores and establishing the sales and internal control structures to support that expansion.」
The company identifies capturing growth opportunities, including M&A, expanding stores, and establishing sales and internal control structures as uses of retained earnings.